Return to ads
All categories


Posted by
Posting ads for 49 years
Johnson & Johnson's (JNJ) $1.5 billion bet to share rights to Elan Corp.'s (ELN) experimental Alzheimer's-disease drugs seems reasonable considering it's a relatively small amount for J&J - and the payoff could be big.

J&J, New Brunswick, N.J., would vault to the forefront of Alzheimer's research by gaining access to Elan's bapineuzumab, a drug that could generate annual sales approaching $6 billion by the end of next decade, estimated Credit Suisse analyst Catherine Arnold.

J&J would have to share the profits with both Elan and its development partner Wyeth (WYE) - which in turn is in the process of being ...
Reply to this ad
Recently viewed ads
Saved ads
Please log in to browse your saved adverts or sign up if you don't have an account yet.
Popular Stuff